Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board
December 20 2023 - 3:30PM
Disc Medicine, Inc. (NASDAQ:IRON) (“Disc”), a clinical-stage
biopharmaceutical company focused on the discovery, development,
and commercialization of novel treatments for patients suffering
from serious hematologic diseases, announced today that, after a
distinguished 28-year career, including over 6 years at Disc, Brian
MacDonald, MB, ChB, PhD, will be retiring from his role as Chief
Innovation Officer. Dr. MacDonald plans to stay involved with Disc,
transitioning from his current role to become Chair of Disc’s
Scientific Advisory Board.
“We are incredibly grateful for all of Brian’s exceptional
contributions and leadership over the past 6 years. As the Founder
and original CEO of Disc, Brian was instrumental in developing the
company’s strong foundation and his visionary leadership has been a
driving force behind Disc’s growth and the innovation that defines
our organization,” said John Quisel, J.D., Ph.D., President and
Chief Executive Officer. “We are thrilled that Brian has agreed to
remain involved with Disc and look forward to his continued
leadership as part of the Scientific Advisory Board. On behalf of
the Board and the entire Disc team, I extend a heartfelt thanks to
Brian for his unwavering commitment to Disc and wish him all the
best in his retirement.”
“It has been an immense privilege to be a part of the leadership
at Disc, which has allowed me to oversee the remarkable growth and
substantial achievements of the company since its inception,” said
Dr. MacDonald. “I am proud of all Disc has accomplished thus far
and am excited to remain a part of Disc’s continued growth towards
becoming a leading hematology company.”
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company
committed to discovering, developing, and commercializing novel
treatments for patients who suffer from serious hematologic
diseases. We are building a portfolio of innovative, potentially
first-in-class therapeutic candidates that aim to address a wide
spectrum of hematologic diseases by targeting fundamental
biological pathways of red blood cell biology, specifically heme
biosynthesis and iron homeostasis. For more information, please
visit www.discmedicine.com.
Disc Medicine Cautionary Statement Regarding
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, including, but not limited to, express or implied statements
regarding Disc’s expectations with respect to the chief innovation
officer position and the contributions of Disc’s scientific
advisory board. The use of words such as, but not limited to,
“believe,” “expect,” “estimate,” “project,” “intend,” “future,”
“potential,” “continue,” “may,” “might,” “plan,” “will,” “should,”
“seek,” “anticipate,” or “could” or the negative of these terms and
other similar words or expressions that are intended to identify
forward-looking statements. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead,
they are based on Disc’s current beliefs, expectations and
assumptions regarding the future of Disc’s business, future plans
and strategies, clinical results and other future conditions. New
risks and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Disc may not actually achieve the plans, intentions or
expectations disclosed in these forward-looking statements, and
investors should not place undue reliance on these forward-looking
statements. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements as a result of a number of material
risks and uncertainties including but not limited to: Disc’s
expectations regarding the chief innovation officer position and
contributions of Disc’s scientific advisory board; Disc’s
expectations regarding leadership, future growth and innovation;
the other risks and uncertainties described in the “Risk Factors”
section of our Annual Report on Form 10-K for the year ended
December 31, 2022, Quarterly Reports on Form 10-Q for the quarters
ended March 31, 2023, June 30, 2023, and September 30, 2023 and
other documents filed by Disc from time to time with the Securities
and Exchange Commission (SEC), as well as discussions of potential
risks, uncertainties, and other important factors in Disc’s
subsequent filings with the SEC. Any forward-looking statement
speaks only as of the date on which it was made. None of Disc, nor
its affiliates, advisors or representatives, undertake any
obligation to publicly update or revise any forward-looking
statement, whether as result of new information, future events or
otherwise, except as required by law.
Media Contact
Peg RusconiVerge Scientific
Communicationsprusconi@vergescientific.com
Investor Relations Contact
Christina TartagliaStern Investor
Relationschristina.tartaglia@sternir.com
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From Apr 2024 to May 2024
Disc Medicine (NASDAQ:IRON)
Historical Stock Chart
From May 2023 to May 2024